Lingling du, MD
Hematology & Oncology · New Orleans, LANPI 1003103532
Payments from drug & device makers
Across 444 payments — averaging $2685.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$498K
- Pfizer$411K
- Genentech, Inc.$69K
- Novartis$52K
- Exelixis Inc.$41K
- AstraZeneca$37K
- plus $85K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 142 | $498,194 |
| Pfizer | 88 | $410,821 |
| Genentech, Inc. | 12 | $68,745 |
| Novartis | 10 | $52,181 |
| Exelixis Inc. | 80 | $40,789 |
| AstraZeneca | 10 | $36,862 |
| Janssen Research & Development, LLC | 1 | $24,500 |
| Incyte Corporation | 44 | $23,019 |
| Ipsen Biopharmaceuticals, Inc | 15 | $20,614 |
| Sirtex Medical Inc | 7 | $4,548 |
| Jazz Pharmaceuticals Inc. | 1 | $3,898 |
| E.r. Squibb & Sons, L.L.C. | 7 | $2,602 |
| Beone Medicines USA, Inc. | 4 | $2,008 |
| Array Biopharma Inc | 2 | $1,890 |
| Eisai Inc. | 2 | $867 |
| Genentech USA, Inc. | 4 | $273 |
| Intera Oncology, Inc | 1 | $202 |
| Trisalus Life Sciences, Inc. | 1 | $160 |
| Tersera Therapeutics LLC | 3 | $83 |
| GSK | 1 | $57 |
| Astellas Pharma US Inc | 3 | $57 |
| Johnson & Johnson | 1 | $48 |
| Masimo Corporation | 1 | $39 |
| Daiichi Sankyo Inc. | 1 | $26 |
| AbbVie | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
How this compares
$1,192,546 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New Orleans
- Marc MatranaNew Orleans$4.6M
- Pedro BarataNew Orleans$4.2M
- Carter DavisNew Orleans$1.6M
- Maissaa JanbainNew Orleans$1.5M
- John ColeNew Orleans$896K
- Cindy LeissingerNew Orleans$432K
- Furhan YunusNew Orleans$422K
- David MorrisonNew Orleans$313K
- Stefan GrantNew Orleans$261K
- Michelle LochNew Orleans$232K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.